Episode Details
Back to Episodes
SF Healthcare Week: Madrigal CEO Bill Sibold talks about the commercialization of the MASH treatment Rezdiffra, and two bolt on deals the company has done for combinations
Published 8 months ago
Description
He discusses the rationale behind acquiring a DGAT-2 and GLP-1, and how a non-pharma sized company has been able to succeed with a new drug launch.